‘This Is Presumably the Most Clearly Unsuitable Recordsdata I Include Considered’: What We Heard This Week
“This is able to per chance well be the most obviously fraudulent files I contain considered.” — Kyle Sheldrick, MBBS, PhD candidate at the University of Novel South Wales, on the without doubt fraudulent files underpinning an depraved survey of nutrition C for sepsis.
“It’s miles OK to contain financial relationships with industry.” — Adam Bitterman, DO, of Northwell Neatly being Doctor Companions Orthopaedic Institute, on rising industry ties amongst U.S. orthopedic journal editorial boards.
“When the unspeakable happens to you, and likewise you focus on it, others contain permission to focus on up too.” — Corey Feist, JD, MBA, president and co-founder of the Dr. Lorna Breen Heroes’ Foundation, on the Dr. Lorna Breen Neatly being Care Provider Protection Act, that can befriend to educate healthcare providers on suicide prevention options and behavioral health.
“For americans who place brushing off polygenic embryo screening…right here is but some other trend that capacity that it would contain utility.” — Gabriel Lázaro-Muñoz, PhD, JD, of Harvard Scientific College, on predicting the risk of traditional ailments within in vitro-fertilized embryos thru unusual tactics.
“We are in grave risk of the ‘Texas sharpshooter fallacy’ — where any individual first fires a shot at a barn then paints a target around the bullet gap.” — Scott Emerson, MD, PhD, of the University of Washington and member of the FDA advisory committee that reviewed aducanumab (Aduhelm), about the importance of prespecified diagnosis plans in scientific trials.
“The performance is the desk dressing for the dialog that follows it.” — Bryan Doerries, ingenious director for Theater of War Productions, on how the Zoom production, The Nurse Antigone, encourages nurses to chat about workforce components.
“The demand is, where’s the elephant within the room?” — Martin Reck, MD, of Scientific institution Grosshansdorf in Germany, on the outcomes of the PEARLS/KEYNOTE-091 trial of adjuvant pembrolizumab in early non-microscopic cell lung cancer.
